Call to Schedule Free Consultation at Over 45 Centers Worldwide!
Autoimmune
Cardiovascular
Endocrine
Gastrointestinal
Liver
Musculoskeletal
Neurological
Other
Respiratory/Pulmonary
Reproductive
Renal/Kidney
Urologic
Autoimmune
Cardiovascular
Endocrine
Gastrointestinal
Liver
Musculoskeletal
Neurological
Other
Respiratory/Pulmonary
Reproductive
Renal/Kidney
Urologic
When it comes to pain management, modern medicine is finally breaking through with regenerative medicine. Rather than dealing with pain from arthritis and soft tissue injuries solely with treatments designed to mask pain, new advancements are working on actually repairing the tissue damage.
Amniotic derived stem cell activator injections are relatively new in the field of regenerative medicine, but their role is becoming more prominent as their potential becomes apparent for musculoskeletal condition repair.
These types of amniotic therapies are not new in medicine, having been used for decades in wound care and other specialties. But in the fields of orthopedics, pain management and rheumatology, amnion is turning out to have the potential for being an effective type of therapy.
It turns out that amniotic fluid is heavily concentrated in growth factors, hyaluronic acid, exosomes, antimicrobial components and stem cell activators that are able to work in a stranger’s body without producing an immunologic rejection response. Who knew?
Here are answers to many of the frequently asked questions we receive.
Stem cells are the most basic cells living in the human body. Their most amazing trait is that they can become many types of cell, from skin cells to muscle, from bone to cartilage. Amniotic stem cells are derived from amniotic fluid obtained during scheduled caesarean sections from consenting donors. Amniotic fluid surrounds the fetus during pregnancy, feeding it. Normally, this fluid is simply discarded. But with the amazing ingredients it contains, now it can be used for those in need.
Researchers have discovered that the amniotic fluid has an extremely high concentration of regenerative cells, even more than bone marrow in adults. When processed at an FDA regulated lab, the biologic material ends up containing significant regenerative properties, such as growth factors, hyaluronic acid and stem cell activators called exosomes. Interestingly, amniotic fluid is actually immunopriviliged, so it does not create a rejection reaction when injected into a patient.
Obtaining stem cells from embryos is considered by many groups to be unethical, but obtaining stem cells and regenerative material from amniotic fluid is not affected by this ethical debate. Amniotic fluid is normally disposed of after.birth, so using it in order to obtain amniotic derived stem cell activator injections does not affect the embryo in any way.There is no harm to the fetus and no blood from the fetus is used, only the amniotic fluid that would be discarded anyway.
Amniotic fluid contains multiple excellent properties for promoting tissue regeneration and repair:
Amniotic stem cell rich treatments have been great for difficult wounds, such as in diabetics.
Amniotic membranes have been used extensively in plastic surgery for treating wounds that have been difficult to heal, as well as opthalmology for helping to heal corneal injury. Amniotic derived stem cell activator injections have been successfully used to promote spinal fusion during surgery, and as a scar barrier around the spinal cord.
Amniotic derived stem cell activator injections have been used over 10,000 times in the US with no reported adverse events, and hundreds of thousands of times in Europe and abroad. There are plenty of anecdotal reports regarding the use of amnion for treating tendinosis and tendinitis of the rotator cuff and elbow tendons. This includes both golfer’s elbow and tennis elbow. Results from these reports have been very promising.
Additionally, anecdotal reports on the use of amnion for joint arthritis in both the spine and extremities has also been encouraging. Surgeons have started using the amnion to supplement surgical repair and reconstruction of ACL’s, Achilles tendons and rotator cuff tendons.
Amniotic derived stem cell activator injections are considered experimental by the FDA. None of the material on this website has been evaluated by the FDA, and no claims are being made. Outcomes vary between individuals.
Studies carried on so far show very promising results. No FDA clinical trials have been performed however.
Recent research has focused on using human amniotic membranes for various indications. Surgical placement of amniotic tissue at the site of laminectomy in canines helped reduce scar tissue significantly. (Tao 2009).
Amniotic fluid rich stem cell medicine offers regenerative potential, anti-inflammation, growth factors and hyaluronic acid.
In a human report, using a human amnion tissue patch after a right l4-5 decompression procedure significantly reduced both scar tissue formation and adherence to the underlying dura (ploska, applied biologics 2012).
R3 Stem Cell is investigating regenerative therapies with an Institutional Review Board (IRB) approved study for several condition categories. Since we do NOT have FDA clinical trial results available, this data will come in very handy in moving the field forward. To read more about the investigational study, visit the information on ClinicalTrials.gov:
Brand Ambassador Gallery
The USA stem cell leader offers procedures in
7 Countries including:
SUCCESS STORIES
R3 STEM CELL MASTER CLASS
Learn everything you need to know about the ever expanding field of regenerative medicine in this 8 part series that includes over four hours of entertaining content!
R3 STEM CELL INTERNATIONAL
R3 Stem Cell International includes 45 clinics in 7 countries. These Centers of Excellence treat all types of conditions with safe, effective protocols by expert stem cell physicians.
FREE STEM CELL CONSULTATION
R3 Stem Cell offers a no cost consultation to see if you or a loved one is a candidate for regenerative cell therapies including cytokines, growth factors, exosomes, and stem cells.
PROVIDER PARTNERSHIP
The R3 Partnership Program offers providers an all-in-one regenerative practice program including marketing, consultations and booked procedures!
The information provided by R3 Stem Cell is not a substitute for professional medical advice, diagnosis, or treatment. Individual results may vary and only your medical professional can explain all the risks and potential benefits of any therapy based on your circumstances. R3 Stem Cell does not recommend or endorse any specific tests, products, procedures, opinions, or other information that may be mentioned on this website. Reliance on any information provided by R3 Stem Cell, its employees, others appearing on this website at the invitation of R3 Stem Cell, or other visitors to the website is solely at your own risk. R3 Stem Cell is not responsible for the outcome of your procedure. The FDA considers stem cell therapy experimental at this point.
CALIFORNIA
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
IOWA
KANSAS
KENTUCKY
LOUISIANA
MARYLAND
MASSACHUSETTS
MICHIGAN
MINNESOTA
MISSISSIPPI
MISSOURI
NEBRASKA
NEW JERSEY
NEW YORK
NEW MEXICO
NEVADA
NORTH CAROLINA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
RHODE ISLAND
SOUTH CAROLINA
SOUTH DAKOTA
TENNESSEE
The USA stem cell leader offers procedures in
7 Countries including:
Copyright © 2017-2024 R3 Stem Cell. All Rights Reserved.